Novo Nordisk Secures Rights to Hengrui Weight Loss Drug for $2.6 Billion

AI-generated NewsSnap summary based on source reporting.
Published: 2026-09-29T11:10:00Z
Category: business
Source: The Guardian
Original source

Novo Nordisk has agreed to pay $2.6 billion to acquire the rights for a weight loss drug developed by Hengrui. This substantial strategic investment aims to expand Novo Nordisk's product portfolio within the rapidly growing global weight loss market, potentially strengthening its competitive position.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai